B-cell activating factor of the tnf family is upregulated in neuromyelitis optica

Neurology

Volumn 74, Issue 2, 2010, Pages 177-178

  Okada, Kazumasa ^a   Matsushita, Takuya ^b   Kira, Jun Ichi ^b   Tsuji, Sadatoshi ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

B CELL ACTIVATING FACTOR;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; MALE; MULTIPLE SCLEROSIS; MYELOOPTIC NEUROPATHY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN EXPRESSION; UPREGULATION;

EID: 75649107856     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3181c919ee     Document Type: Article

References (7)

1. Wingerchuk DM, Lennon VA, Lucchinetti CF, et al. The spectrum of neuromyelitis optica. Lancet Neurol 2007;6: 805-815.
2. Krumbholz M, Faber H, Steinmeyer F, et al. Interferon-B increases BAFF levels in multiple sclerosis: implication for B cell autoimmunity. Brain 2008;131:1455-1463.
3. Mackay F, Silveira PA, Brink R. B cells and the BAFF/ APRIL axis: fast-forward on autoimmunity and signaling. Curr Opin Immunol 2007;19:327-336.
4. Matsuoka T, Matsushita T, Kawano Y, et al. Heterogeneity of aquaporin-4 autoimmunity and spinal cord lesions in multiple sclerosis in Japanese. Brain 2007;130:1206-1223.
5. Wingerchuk DM, Lennon VA, Pittoch SJ, et al. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006;66:1485-1489.
6. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald criteria." Ann Neurol 2005;58:840-846.
7. Jacob A, Weinshenker BG, Violich I, et al. Treatment of neuromyelitis optica with rituximab. Arch Neurol 2008; 65:1443-1448.